title: Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients.
authors.forename: Sonja
authors.initials: S
authors.lastname: Jacob
authors.forename: Burkhard
authors.initials: B
authors.lastname: Poeggeler
authors.forename: Jochen H
authors.initials: JH
authors.lastname: Weishaupt
authors.forename: Anna-Leena
authors.initials: AL
authors.lastname: Sirén
authors.forename: Rüdiger
authors.initials: R
authors.lastname: Hardeland
authors.forename: Mathias
authors.initials: M
authors.lastname: Bähr
authors.forename: Hannelore
authors.initials: H
authors.lastname: Ehrenreich
mesh_terms: D000284:Administration, Oral; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D000975:Antioxidants / Q000008:administration & dosage; D004361:Drug Tolerance; D006801:Humans; D008550:Melatonin / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D018384:Oxidative Stress / Q000187:drug effects; D010865:Pilot Projects
chemical_list: D000975:Antioxidants; D018696:Neuroprotective Agents; D008550:Melatonin